Detalles de la búsqueda
1.
Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers.
Breast Cancer Res Treat
; 183(1): 95-105, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32601968
2.
Epigenetic genes regulated by the BRAFV600E signaling are associated with alterations in the methylation and expression of tumor suppressor genes and patient survival in melanoma.
Biochem Biophys Res Commun
; 425(1): 45-50, 2012 Aug 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-22820187
3.
Expression of NOTCH1, NOTCH4, HLA-DMA and HLA-DRA is synergistically associated with T cell exclusion, immune checkpoint blockade efficacy and recurrence risk in ER-negative breast cancer.
Cell Oncol (Dordr)
; 45(3): 463-477, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35543859
4.
Mutations in KMT2C, BCOR and KDM5C Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer.
Cancers (Basel)
; 14(11)2022 Jun 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35681795
5.
A Novel Metabolic Reprogramming Strategy for the Treatment of Diabetes-Associated Breast Cancer.
Adv Sci (Weinh)
; 9(6): e2102303, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35023320
6.
Basal-like breast cancer with low TGFß and high TNFα pathway activity is rich in activated memory CD4 T cells and has a good prognosis.
Int J Biol Sci
; 17(3): 670-682, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33767579
7.
BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus.
Int J Cancer
; 127(12): 2965-73, 2010 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21351275
8.
AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer.
Cell Oncol (Dordr)
; 43(2): 321-333, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31933152
9.
Association of an anaplastic lymphoma kinase pathway signature with cell de-differentiation, neoadjuvant chemotherapy response, and recurrence risk in breast cancer.
Cancer Commun (Lond)
; 40(9): 422-434, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32822101
10.
BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.
Clin Breast Cancer
; 20(1): 41-50.e8, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31547956
11.
Concomitant dysregulation of the estrogen receptor and BRAF/MEK signaling pathways is common in colorectal cancer and predicts a worse prognosis.
Cell Oncol (Dordr)
; 42(2): 197-209, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30645729
12.
Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer.
Endocr Relat Cancer
; 15(1): 183-90, 2008 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-18310286
13.
Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways.
Thyroid
; 18(8): 853-64, 2008 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-18651802
14.
Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
Clin Cancer Res
; 13(4): 1341-9, 2007 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17317846
15.
Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.
Clin Cancer Res
; 13(4): 1161-70, 2007 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17317825
16.
BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells.
J Clin Endocrinol Metab
; 92(6): 2264-71, 2007 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-17374713
17.
Lack of mutations in the thyroid hormone receptor (TR) alpha and beta genes but frequent hypermethylation of the TRbeta gene in differentiated thyroid tumors.
J Clin Endocrinol Metab
; 92(12): 4766-70, 2007 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-17911173
18.
Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.
J Clin Endocrinol Metab
; 92(12): 4686-95, 2007 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-17911174
19.
High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors.
J Clin Endocrinol Metab
; 92(6): 2387-90, 2007 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-17426084
20.
ZBED2 expression enhances interferon signaling and predicts better survival of estrogen receptor-negative breast cancer patients.
Cancer Commun (Lond)
; 42(7): 663-667, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35486908